Combination of a hypomethylating agent and inhibitors of PARP and HDAC traps PARP1 and DNMT1 to chromatin, acetylates DNA repair proteins, down-regulates NuRD and induces apoptosis in human leukemia and lymphoma cells

Combination of drugs that target different aspects of aberrant cellular processes is an efficacious treatment for hematological malignancies. Hypomethylating agents (HMAs) and inhibitors of poly(ADP-ribose) polymerases (PARPis) and histone deacetylases (HDACis) are clinically active anti-tumor drugs...

Descripción completa

Detalles Bibliográficos
Autores principales: Valdez, Benigno C., Li, Yang, Murray, David, Liu, Yan, Nieto, Yago, Champlin, Richard E., Andersson, Borje S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5790510/
https://www.ncbi.nlm.nih.gov/pubmed/29423093
http://dx.doi.org/10.18632/oncotarget.23386

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5790510/
https://www.ncbi.nlm.nih.gov/pubmed/29423093
http://dx.doi.org/10.18632/oncotarget.23386

Ejemplares similares